INNPF
InnoCan Pharma Corporation
Price Chart
Latest Quote
$2.10
+0.00 (+0.00%)
Current Price
| Previous Close | $2.10 |
| Open | $2.10 |
| Day High | $2.10 |
| Day Low | $2.09 |
| Volume | 200 |
Stock Information
| Shares Outstanding | 4.50M |
| Total Debt | $1.42M |
| Cash Equivalents | $6.63M |
| Revenue | $25.28M |
| Net Income | $-1.51M |
| Sector | Consumer Defensive |
| Industry | Household & Personal Products |
| Market Cap | $9.45M |
| EPS (TTM) | $-0.34 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $6.96M |
| Sales | $25.28M |
| Income | $-1.51M |
| Book/sh | $1.16 |
| Cash/sh | $1.47 |
Financial Ratios
| Quick Ratio | 4.06 |
| Current Ratio | 5.51 |
| Debt/Eq | 17.89 |
Returns & Margins
| ROA | -14.60% |
| ROE | -13.47% |
| Gross Margin | 89.81% |
| Operating Margin | -12.16% |
| Profit Margin | -5.99% |
Ownership
| Insider Ownership | 22.62% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 0.37 |
| P/B | 1.82 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $2.39 |
| SMA50 | $3.55 |
| SMA200 | $6.95 |
| ATR | 0.0250 |
| Shares Float | 3.58M |
| Volatility | -0.27 |
Performance History
| Week | -12.50% |
| Month | -30.69% |
| Quarter | -57.58% |
| 6 Months | -70.95% |
| YTD | -70.95% |
| Year | -59.62% |
| 3 Years | -82.72% |
| 5 Years | -91.82% |
| 10 Years | -83.23% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $2.10 | 0 |
| 2026-06-23 | $2.10 | 0 |
| 2026-06-22 | $2.10 | 100 |
| 2026-06-18 | $2.40 | 0 |
| 2026-06-17 | $2.40 | 0 |
| 2026-06-16 | $2.40 | 0 |
| 2026-06-15 | $2.40 | 0 |
| 2026-06-12 | $2.40 | 0 |
| 2026-06-11 | $2.40 | 0 |
| 2026-06-10 | $2.40 | 0 |
| 2026-06-09 | $2.40 | 0 |
| 2026-06-08 | $2.40 | 100 |
| 2026-06-05 | $2.45 | 0 |
| 2026-06-04 | $2.45 | 0 |
| 2026-06-03 | $2.45 | 0 |
| 2026-06-02 | $2.45 | 200 |
| 2026-06-01 | $2.50 | 0 |
| 2026-05-29 | $2.50 | 0 |
| 2026-05-28 | $2.50 | 0 |
| 2026-05-27 | $2.50 | 300 |
| 2026-05-26 | $2.67 | 159 |
About InnoCan Pharma Corporation
InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations. The company develops a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is in the preclinical trial phase to treat chronic pain management for human and veterinary health sectors. It also offers a pain-relieving topical composition, as well as compositions for the treatment of hemorrhoid, psoriasis of the scalp, vaginal atrophy, and diabetic symptoms. The company is also involved in development, manufacture, and marketing of cosmetic products. InnoCan Pharma Corporation was founded in 2017 and is headquartered in Calgary, Canada.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $3,250,000 | $1,679,000 | $452,000 | $75,000 |
| Cost Of Revenue | $3,250,000 | $1,679,000 | $452,000 | $75,000 |
| Total Revenue | $29,437,000 | $13,657,000 | $2,559,000 | $196,000 |
| Operating Revenue | $29,437,000 | $13,657,000 | $2,559,000 | $196,000 |
| Expenses | ||||
| Interest Expense | $7,000 | $0 | $2,000 | $13,000 |
| Total Expenses | $30,684,000 | $17,460,000 | $8,825,000 | $7,676,000 |
| Other Income Expense | $2,173,000 | $-254,000 | $2,359,000 | $-2,598,000 |
| Net Non Operating Interest Income Expense | $-7,000 | $23,000 | $19,000 | $-13,000 |
| Interest Expense Non Operating | $7,000 | $0 | $2,000 | $13,000 |
| Operating Expense | $27,434,000 | $15,781,000 | $8,373,000 | $7,601,000 |
| Selling And Marketing Expense | $21,132,000 | $10,469,000 | $2,864,000 | $1,405,000 |
| General And Administrative Expense | $4,753,000 | $3,516,000 | $3,983,000 | $4,797,000 |
| Rent Expense Supplemental | - | $112,000 | $198,000 | $84,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,834,000 | $-4,700,000 | $-3,764,000 | $-10,047,000 |
| Net Interest Income | $-7,000 | $23,000 | $19,000 | $-13,000 |
| Interest Income | $0 | $23,000 | $21,000 | - |
| Normalized Income | $-3,681,050 | $-4,547,600 | $-5,504,706 | $-7,449,000 |
| Net Income From Continuing And Discontinued Operation | $-1,834,000 | $-4,700,000 | $-3,764,000 | $-10,047,000 |
| Total Operating Income As Reported | $-1,247,000 | $-3,803,000 | $-6,266,000 | $-7,480,000 |
| Net Income Common Stockholders | $-1,834,000 | $-4,700,000 | $-3,764,000 | $-10,047,000 |
| Net Income | $-1,834,000 | $-4,700,000 | $-3,764,000 | $-10,047,000 |
| Net Income Including Noncontrolling Interests | $-262,000 | $-4,248,000 | $-3,889,000 | $-10,091,000 |
| Net Income Continuous Operations | $-262,000 | $-4,248,000 | $-3,889,000 | $-10,091,000 |
| Pretax Income | $919,000 | $-4,034,000 | $-3,888,000 | $-10,091,000 |
| Interest Income Non Operating | $0 | $23,000 | $21,000 | - |
| Operating Income | $-1,247,000 | $-3,803,000 | $-6,266,000 | $-7,480,000 |
| Gross Profit | $26,187,000 | $11,978,000 | $2,107,000 | $121,000 |
| Per Share | ||||
| Diluted EPS | $-0.65 | $-1.30 | $-1.04 | $-3.25 |
| Basic EPS | $-0.65 | $-1.30 | $-1.04 | $-3.25 |
| Other | ||||
| Tax Effect Of Unusual Items | $325,950 | $-101,600 | $618,294 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,212,000 | $-3,747,000 | $-6,210,000 | $-7,437,000 |
| Total Unusual Items | $2,173,000 | $-254,000 | $2,359,000 | $-2,598,000 |
| Total Unusual Items Excluding Goodwill | $2,173,000 | $-254,000 | $2,359,000 | $-2,598,000 |
| Reconciled Depreciation | $35,000 | $33,000 | $35,000 | $43,000 |
| EBITDA (Bullshit earnings) | $961,000 | $-4,001,000 | $-3,851,000 | $-10,035,000 |
| EBIT | $926,000 | $-4,034,000 | $-3,886,000 | $-10,078,000 |
| Diluted Average Shares | $4,308,320 | $3,953,904 | $3,830,049 | $3,454,488 |
| Basic Average Shares | $4,308,320 | $3,953,904 | $3,830,049 | $3,454,488 |
| Diluted NI Availto Com Stockholders | $-1,834,000 | $-4,700,000 | $-3,764,000 | $-10,047,000 |
| Minority Interests | $-1,572,000 | $-452,000 | $125,000 | $44,000 |
| Tax Provision | $1,181,000 | $214,000 | $1,000 | $0 |
| Gain On Sale Of Security | $2,173,000 | $-254,000 | $2,359,000 | $-2,598,000 |
| Research And Development | $1,549,000 | $1,796,000 | $1,526,000 | $1,399,000 |
| Selling General And Administration | $25,885,000 | $13,985,000 | $6,847,000 | $6,202,000 |
| Other Gand A | $1,989,000 | $1,868,000 | $1,728,000 | $1,320,000 |
| Salaries And Wages | $2,764,000 | $1,648,000 | $1,849,000 | $3,221,000 |
| Insurance And Claims | - | $145,000 | $208,000 | $172,000 |
| Rent And Landing Fees | - | $112,000 | $198,000 | $84,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,167,000 | $4,103,000 | $6,394,000 | $9,055,000 |
| Total Assets | $9,260,000 | $6,940,000 | $6,976,000 | $12,575,000 |
| Total Non Current Assets | $113,000 | $136,000 | $98,000 | $54,000 |
| Current Assets | $9,147,000 | $6,804,000 | $6,878,000 | $12,521,000 |
| Other Current Assets | $150,000 | $28,000 | - | - |
| Restricted Cash | $69,000 | $138,000 | $104,000 | $79,000 |
| Prepaid Assets | $67,000 | $340,000 | $453,000 | $715,000 |
| Inventory | $3,317,000 | $1,747,000 | $1,131,000 | $510,000 |
| Receivables | $536,000 | $666,000 | $243,000 | $963,000 |
| Other Receivables | $250,000 | $232,000 | $83,000 | $963,000 |
| Taxes Receivable | $286,000 | $417,000 | $145,000 | $135,000 |
| Accounts Receivable | $0 | $17,000 | $15,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $5,008,000 | $3,885,000 | $4,947,000 | $11,048,000 |
| Cash And Cash Equivalents | $5,008,000 | $3,885,000 | $4,947,000 | $11,048,000 |
| Cash Equivalents | $0 | $142,000 | $1,509,000 | - |
| Cash Financial | $5,008,000 | $3,743,000 | $3,438,000 | - |
| Debt | ||||
| Total Debt | $10,000 | $33,000 | $34,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $0 | $11,000 | $20,000 | $0 |
| Current Debt And Capital Lease Obligation | $10,000 | $22,000 | $14,000 | $1,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,238,000 | $2,554,000 | $751,000 | $3,564,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $11,000 | $20,000 | $0 |
| Current Liabilities | $2,238,000 | $2,543,000 | $731,000 | $3,564,000 |
| Other Current Liabilities | $1,565,000 | $1,946,000 | $304,000 | $3,078,000 |
| Payables And Accrued Expenses | $663,000 | $575,000 | $413,000 | $486,000 |
| Payables | $185,000 | $112,000 | $95,000 | $486,000 |
| Accounts Payable | $185,000 | $112,000 | $95,000 | $53,000 |
| Other Payable | - | - | - | $433,000 |
| Equity | ||||
| Common Stock Equity | $5,167,000 | $4,103,000 | $6,394,000 | $9,055,000 |
| Total Equity Gross Minority Interest | $7,022,000 | $4,386,000 | $6,225,000 | $9,011,000 |
| Stockholders Equity | $5,167,000 | $4,103,000 | $6,394,000 | $9,055,000 |
| Retained Earnings | $-34,908,000 | $-33,074,000 | $-28,374,000 | $-24,610,000 |
| Other | ||||
| Ordinary Shares Number | $4,463,315 | $4,123,106 | $3,841,970 | $3,823,017 |
| Share Issued | $4,463,315 | $4,123,106 | $3,841,970 | $3,823,017 |
| Tangible Book Value | $5,167,000 | $4,103,000 | $6,394,000 | $9,055,000 |
| Invested Capital | $5,167,000 | $4,103,000 | $6,394,000 | $9,055,000 |
| Working Capital | $6,909,000 | $4,261,000 | $6,147,000 | $8,957,000 |
| Capital Lease Obligations | $10,000 | $33,000 | $34,000 | $0 |
| Total Capitalization | $5,167,000 | $4,103,000 | $6,394,000 | $9,055,000 |
| Minority Interest | $1,855,000 | $283,000 | $-169,000 | $-44,000 |
| Additional Paid In Capital | $40,075,000 | $37,177,000 | $34,768,000 | $33,665,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $11,000 | $20,000 | $0 |
| Current Capital Lease Obligation | $10,000 | $22,000 | $14,000 | $1,000 |
| Current Accrued Expenses | $478,000 | $463,000 | $318,000 | $432,000 |
| Net PPE | $113,000 | $136,000 | $98,000 | $54,000 |
| Gross PPE | $113,000 | $136,000 | $98,000 | $54,000 |
| Other Properties | $113,000 | $136,000 | $98,000 | $54,000 |
| Inventories Adjustments Allowances | $-137,000 | $0 | - | - |
| Other Inventories | $184,000 | $214,000 | $224,000 | $188,000 |
| Finished Goods | $3,270,000 | $1,533,000 | $907,000 | $322,000 |
| Raw Materials | - | - | $224,000 | $188,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-1,594,000 | $-3,950,000 | $-6,093,000 | $-6,670,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-1,579,000 | $-3,904,000 | $-6,067,000 | $-6,629,000 |
| Cash Flow From Continuing Operating Activities | $-1,579,000 | $-3,904,000 | $-6,067,000 | $-6,629,000 |
| Operating Gains Losses | $-2,215,000 | $258,000 | $-2,774,000 | $2,308,000 |
| Investing Activities | ||||
| Capital Expenditure | $-15,000 | $-46,000 | $-26,000 | $-41,000 |
| Investing Cash Flow | $54,000 | $-84,000 | $-31,000 | $-48,000 |
| Cash Flow From Continuing Investing Activities | $54,000 | $-84,000 | $-31,000 | $-48,000 |
| Net Other Investing Changes | $69,000 | $-38,000 | $-5,000 | $-7,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $891,000 | $1,555,000 | $0 | $3,914,000 |
| Financing Cash Flow | $2,704,000 | $2,917,000 | $125,000 | $15,303,000 |
| Cash Flow From Continuing Financing Activities | $2,704,000 | $2,917,000 | $125,000 | $15,303,000 |
| Net Common Stock Issuance | $891,000 | $1,555,000 | $0 | $3,914,000 |
| Common Stock Issuance | $891,000 | $1,555,000 | $0 | $3,914,000 |
| Other | ||||
| Repayment Of Debt | $-22,000 | $-22,000 | $-11,000 | $-38,000 |
| End Cash Position | $5,008,000 | $3,885,000 | $4,947,000 | $11,048,000 |
| Beginning Cash Position | $3,885,000 | $4,947,000 | $11,048,000 | $2,338,000 |
| Effect Of Exchange Rate Changes | $-56,000 | $9,000 | $-128,000 | $84,000 |
| Changes In Cash | $1,179,000 | $-1,071,000 | $-5,973,000 | $8,626,000 |
| Proceeds From Stock Option Exercised | $1,835,000 | $1,384,000 | $136,000 | $11,427,000 |
| Net Issuance Payments Of Debt | $-22,000 | $-22,000 | $-11,000 | $-38,000 |
| Net Long Term Debt Issuance | $-22,000 | $-22,000 | $-11,000 | $-38,000 |
| Long Term Debt Payments | $-22,000 | $-22,000 | $-11,000 | $-38,000 |
| Net PPE Purchase And Sale | $-15,000 | $-46,000 | $-26,000 | $-41,000 |
| Purchase Of PPE | $-15,000 | $-46,000 | $-26,000 | $-41,000 |
| Interest Received Cfo | $59,000 | - | - | - |
| Interest Paid Cfo | $59,000 | $-8,000 | - | - |
| Change In Working Capital | $-1,203,000 | $-793,000 | $-531,000 | $-969,000 |
| Change In Other Current Assets | $264,000 | $-336,000 | - | - |
| Change In Payables And Accrued Expense | $86,000 | $161,000 | $-73,000 | $-425,000 |
| Change In Payable | $86,000 | $161,000 | $-73,000 | $-425,000 |
| Change In Account Payable | $72,000 | $17,000 | $42,000 | $-474,000 |
| Change In Inventory | $-1,570,000 | $-616,000 | $-621,000 | $-79,000 |
| Change In Receivables | $17,000 | $-2,000 | $163,000 | $-465,000 |
| Changes In Account Receivables | $17,000 | $-2,000 | $-15,000 | $2,000 |
| Stock Based Compensation | $2,007,000 | $854,000 | $967,000 | $2,163,000 |
| Depreciation Amortization Depletion | $35,000 | $33,000 | $35,000 | $43,000 |
| Depreciation And Amortization | $35,000 | $33,000 | $35,000 | $43,000 |
| Depreciation | $35,000 | $33,000 | $35,000 | $43,000 |
| Gain Loss On Investment Securities | $-2,215,000 | $258,000 | $-2,774,000 | $2,308,000 |
| Net Income From Continuing Operations | $-262,000 | $-4,248,000 | $-3,889,000 | $-10,091,000 |
| Other Non Cash Items | - | $-8,000 | $125,000 | $-83,000 |
Fetched: 2026-02-02